Noids in a nutshell: Everything you (don’t) want to know about synthetic cannabimimetics

Advances in Dual Diagnosis

Volumn 7, Issue 3, 2014, Pages 137-148

  Papanti, Duccio ^a   Orsolini, Laura ^b   Francesconi, Giulia ^b   Schifano, Fabrizio ^c  

^a UNIVERSITY OF TRIESTE   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^c UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

Author keywords

Psychosis; Schizophrenia; Spice; Substance misuse; Synthetic cannabimimetics; Synthetic cannabinoids

Indexed keywords

EID: 84921901942     PISSN: 17570972     EISSN: 20428324     Source Type: Journal    
DOI: 10.1108/ADD-02-2014-0006     Document Type: Review

References (114)

1. Alhadi, S., Tiwari, A., Vohra, R., Gerona, R., Acharya, J. and Bilello, K. (2013), “High times, low SATS: diffuse pulmonary infiltrates associated with chronic synthetic cannabinoid use”, Journal of Medical Toxicology, Vol. 9 No. 2, pp. 199-206.
2. Àlvarez, Y., Pèrez-Mañà, C., Torrens, M. and Farrè, M. (2013), “Antipsychotic drugs in cocaine dependence: a systematic review and meta-analysis”, Journal of Substance Abuse Treatment, Vol. 45 No. 1, pp. 1-10.
3. Ashton, C.H. (2001), “Pharmacology and effects of cannabis: a brief review”, The British Journal of Psychiatry, Vol. 178, pp. 101-6.
4. Assi, S., Fergus, S., Stair, J., Corazza, O. and Schifano, F. (2011), “Emergence and identification of new designer drug products from the internet”, European Pharmaceutical Review, Vol. 16 No. 4, pp. 68-72.
5. Auwärter, V., Dargan, P.I. and Wood, D.M. (2013), “Synthetic cannabinoid receptor agonists”, in Dargan, P.I. and Wood, D.M. (Eds), Novel Psychoactive Substances: Classification, Pharmacology and Toxicology, Elsevier, London, pp. 317-43.
6. Auwärter, V., Dresen, S., Weinmann, W., Muller, M., Putz, M. and Ferreiròs, N. (2009), “‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs?”, Journal of Mass Spectrometry, Vol. 44 No. 5, pp. 832-7.
7. Bossong, M.G. and Niesink, R.J.M. (2010), “Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia”, Progress in Neurobiology, Vol. 92 No. 3, pp. 370-85.
8. Boyer, E.W. and Shannon, M. (2005), “The serotonin syndrome”, New England Journal of Medicine, Vol. 352 No. 11, pp. 1112-20.
9. Brents, L.K. and Prather, P.L. (2014), “The K2/spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products”, Drug Metabolism Reviews, Vol. 46 No. 1, pp. 72-85.
10. Brents, L.K., Gallus-Zawada, A., Radominska-Pandya, A., Vasilijevik, T., Prisinzano, T.E., Fantegrossi, W.E., Moran, J.H. and Prather, P.L. (2012), “Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity”, Biochemical Pharmacology, Vol. 83 No. 7, pp. 952-61.
11. Brents, L.K., Reichard, E.E., Zimmerman, S.M., Moran, J.H., Fantegrossi, W.E. and Prather, P.L. (2011), “Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity”, PLoS One, Vol 6 No. 7, pp. 1-9.
12. Brents, L.K., Zimmerman, S.M., Saffell, A.R., Prather, P.L. and Fantegrossi, W.E. (2013), “Differential drug-interactions of the synthetic cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy”, Journal of Pharmacology and Experimental Therapeutics, Vol. 346 No. 3, pp. 350-61.
13. Centers for Disease Control and Prevention (2012), “Acute kidney injury associated with synthetic cannabinoid use – multiple states, 2012”, Morbidity and Mortality Weekly Report, Vol. 62 No. 6, pp. 93-8.
14. Chambers, R.A., Taylor, J.R. and Potenza, M.N. (2003), “Developmental neurocircuitry of motivation in adolescence: a critical period of addiction vulnerability”, American Journal of Psychiatry, Vol. 160 No. 6, pp. 1041-52.
15. Chan, W.L., Wood, D.M., Hudson, S. and Dargan, P.I. (2013), “Acute psychosis associated with recreational use of benzofuran 6-(2-aminopropyl)benzofuran (6-APB) and cannabis”, Journal of Medical Toxicology, Vol. 9 No. 3, pp. 278-81.
16. Chimalakonda, K.C., Seely, K.A., Bratton, S.M., Brents, L.K., Moran, C.L., Endres, G.W., James, L.P., Hollenberg, P.F., Radominska-Pandya, A. and Moran, J.H. (2012), “Cytochrome p450-mediated oxidative metabolism of abused synthetic cannabinoids found in k2/spice: identification of novel cannabinoid receptor ligands”, Drug Metabolism and Disposition, Vol. 40 No. 11, pp. 2174-84.
17. Corkery, J., Claridge, H., Loi, B., Goodair, C. and Schifano, F. (2014), “NPSAD Annual report 2013 – drug-related deaths in the UK: January-December 2012”, International Centre for Drug Policy (ICDP), St George’s, University of London, Cranmer Terrace, London SW17 0RE, ISBN: 978-1-897778-9-2.
18. Daly, M. (2013), “Streets legal”, Druglink, Vol. 28 No. 6, p. 17.
19. Di Forti, M., Morgan, C., Dazzan, P., Pariante, C., Mondelli, V., Marques, T.R., Handley, R., Luzi, S., Russo, M., Paparelli, A., Butt, A., Stilo, S.A., Wiffen, B., Powell, J. and Murray, R.M. (2009), “High-potency cannabis and the risk of psychosis”, British Journal of Psychiatry, Vol. 195 No. 6, pp. 488-91.
20. Dillon, P. and Copeland, J. (2012), “Synthetic cannabinoids: the Australian experience”, NCPIC Bullettin Series 13, March, pp. 1-10.
21. Drug Enforcement Administration (2014), “Schedules of controlled substances: temporary placement of four synthetic cannabinoids into schedule I”, available at: www.deadiversion.usdoj.gov/fed_regs/rules/2014/fr0110_10.htm (accessed 10 February 2014)
22. Drugs-Forum (2012), “Tips and tricks to beating a synthetic cannabinoid overdose”, available at: www.drugs-forum.com/forum/showthread.php?t¼180256 (accessed 6 February 2014)
23. Drugs-Forum (2013), “Spice article”, available at: www.drugs-forum.com/forum/showwiki.php?title¼ Spice/ (accessed 6 February 2014)
24. D’Souza, C., Perry, E., Mac Dougall, L., Yola Ammerman, Y., Cooper, T., Wu, Y., Braley, G., Gueorguieva, R. and Krystal, J.H. (2004), “The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis”, Neuropsychopharmacology, Vol. 29 No. 8, pp. 1558-72
25. Erowid (2012), “Excessive cannabinoid agonism: an experience with Spice and AM2201”, available at: www.erowid. org/experiences/ exp.php?ID¼96704 (accessed 10 February 2014)
26. European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) (2009), “Understanding the ‘Spice’ phenomenon”, Lisbon, available at: www.emcdda.europa.eu/attachements. cfm/att_80086_EN_ EMCDDA_Understanding% 20the%20’ Spice’% 20phenomenon_4Update%2020090813.pdf (accessed 15 April 2014)
27. European Monitoring Centre for Drugs and Drug Addiction (2013), “Perspectives on drugs: synthetic cannabinoids in Europe”, available at: www.emcdda.europa.eu/topics/pods/synthetic-cannabinoids (accessed 15 April 2014)
28. Fadda, P., Scherma, M. and Spano, M.S. (2006), “Cannabinoid selfadministration increases dopamine release in the nucleus accumbens”, NeuroReport, Vol. 17 No. 15, pp. 1629-32.
29. Fantegrossi, W.E., Murnane, K.S. and Reissig, C.J. (2008), “The behavioral pharmacology of hallucinogens”, Biochemical Pharmacology, Vol. 75 No. 1, pp. 17-33.
30. Fantegrossi, W.E., Moran, J.H., Radominska-Pandya, A. and Prather, P.L. (2013), “Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to D9-THC: mechanism underlying greater toxicity?”, Life Sciences, Vol. 97 No. 1, pp. 45-54.
31. Fattore, L. and Fratta, W. (2011), “Beyond THC: the new generation of cannabinoid designer drugs”, Frontiers in Behavioural Neurosciences, Vol. 21 No. 5, pp. 1-11.
32. Fisar, Z. (2010), “Inhibition of monoamine oxidase activity by cannabinoids”, Naunyn-Schmiedeberg’s Archives of Pharmacology, Vol. 381 No. 6, pp. 563-72.
33. Franklin, J.M. and Carrasco, G.A. (2013), “Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling”, Synapse, Vol. 67 No. 3, pp. 145-59.
34. Franklin, J.M., Vasiljevik, T., Prisinzano, T.E. and Carrasco, G.A. (2012), “Cannabinoid 2 receptor- and beta arrestin 2-dependent upregulation of serotonin 2A receptors”, European Neuropsychopharmacology, Vol. 23 No. 7, pp. 760-7.
35. Freeman, M.J., Rose, D.Z., Myers, M.A., Gooch, C.L., Bozeman, A.C. and Burgin, W.S. (2013), “Ischemic stroke after use of the synthetic marijuana ‘spice’”, Neurology, Vol. 81 No. 24, pp. 2090-3.
36. Freeman, W.D., Jacksonville, F.L. and Louh, I.K. (2014), “Spice encephalopathy”, Neurology, published online, response to “Ischemic stroke after use of the synthetic marijuana ‘spice’”, Vol. 81 No. 24, pp. 2090-93, available at: www.neurology.org/content/81/24/2090/reply/ (accessed 5 February 2014)
37. Froberg, B.A. and Bauer, B.D. (2012), “Pneumorachis, pneumomediastinum, and subcutaneous emphysema after synthetic cannabinoid use”, Clinical Toxicology, Vol. 50 No. 7, p. 705.
38. Glue, P., Al-Shaqsi, S., Hancock, D., Gale, C., Strong, B. and Schep, L. (2013), “Hospitalisation associated with use of the synthetic cannabinoid K2”, The New Zealand Medical Journal, Vol. 126 No. 1377, pp. 18-22.
39. Grotenhermen, F. (2003), “Pharmacokinetics and pharmacodynamics of cannabinoids”, Clinical Pharmacokinetics, Vol. 42 No. 4, pp. 327-60.
40. Gunderson, E.W., Haughey, H.M., Ait-Daoud, N., Joshi, A.S. and Hart, C.L. (2012), “‘Spice’ and ‘K2’ herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans”, American Journal of Addiction, Vol. 21 No. 4, pp. 320-6.
41. Gurney, S.M.R., Scott, K.S., Kacinko, S.L., Presley, B.C. and Logan, B.K. (2014), “Pharmacology, toxicology, and adverse effects of synthetic cannabinoid drugs”, Forensic Sciences Review, Vol. 56 No. 53, pp. 53-56.
42. Halberstadt, A.L. and Geyer, M.A. (2011), “Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens”, Neuropharmacology, Vol. 61 No. 3, pp. 364-81.
43. Heltsley, R., Shelby, M.K., Crouch, D.J., Black, D.L., Robert, T.A., Marshall, L., Bender, C.L., DePriest, A.Z. and Colello, M.A. (2012), “Prevalence of synthetic cannabinoids in US athletes: initial findings”, Journal of Analytical Toxicology, Vol. 36 No. 8, pp. 588-93.
44. Hermanns-Clausen, M., Kneisel, S., Szabo, B. and Auwärter, V. (2013), “Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings”, Addiction, Vol. 108 No. 3, pp. 534-44.
45. Hurst, D., Loeffler, G. and McLay, R. (2010), “Synthetic cannabinoid agonist induced psychosis: a case series”, poster presented at the American Psychiatry Association (APA), Naval Medical Centre, San Diego, CA, August-December, available at: www.ncis.navy.mil/PI/CRP/Documents/Spice%20APA%20poster.pdf (accessed 6 March 2014)
46. Hutchins, B.I. (2013), “Neuro(re)development of brain circuitry: linking cell biology to psychiatric discoveries”, Frontiers in Psychiatry, Vol. 4 No. 65, pp. 1-2.
47. Johnston, L.D., O’Malley, P.M., Bachman, J.G. and Schulenberg, J.E. (2013), Monitoring the Future National Survey Results on Drug Use, 1975-2012. Volume I: Secondary School Students, Institute for Social Research, The University of Michigan, Ann Arbor, MI, 604pp
48. Kavanagh, P., Grigoryev, A., Savchuk, S., Mikhura, I. and Formanovsky, A. (2013), “UR-144 in products sold via the internet: identification of related compounds and characterization of pyrolysis products”, Drug Test and Analysis, Vol. 5 No. 8, pp. 683-92.
49. Kronstrand, R., Roman, M., Andersson, M. and Eklund, A. (2013), “Toxicological findings of synthetic cannabinoids in recreational users”, Journal of Analytical Toxicology, Vol. 37 No. 8, pp. 534-41.
50. Lank, P.M., Pines, E. and Mycyk, M.B. (2013), “Emergency physicians’ knowledge of cannabinoid designer drugs”, Western Journal of Emergency Medicine, Vol. 14 No. 5, pp. 467-70.
51. Large, M., Sharma, S., Compton, M., Slade, T. and Nielssen, O. (2011), “Cannabis use and earlier onset of psychosis”, Archives of General Psychiatry, Vol. 68 No. 6, pp. 555-61.
52. Lewin, A.H., Seltzman, H.H., Carroll, F.I., Mascarella, S.W. and Reddy, A. (2013), “Emergence and properties of spice and bath salts: a medicinal chemistry perspective”, Life Sciences, Vol. 97 No. 1, pp. 9-19.
53. Malone, D.T., Hill, N.H. and Rubino, T. (2010), “Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models”, British Journal of Psychiatry, Vol. 160 No. 3, pp. 511-22.
54. Mecholaum, R., Peters, M., Murillo-Rodriguez, E. and Hanus, L.O. (2007), “Cannabidiol – recent advances”, Chemistry & Biodiversity, Vol. 4 No. 8, pp. 1678-92.
55. Mir, A., Obafemi, A., Young, A. and Kane, C. (2011), “Myocardial infarction associated with use of the synthetic cannabinoid K2”, Pediatrics, Vol. 128 No. 6, pp. e1622-e1627.
56. Molina-Holgado, E., Vela, J.M., Arevalo-Martin, A., Almazan, G., Molina-Holgado, F., Borrell, J. and Guaza, C. (2002), “Cannabinoids promote oligodendrocyte progenitor survival: involvement of cannabinoid receptors and phosphatidylinositol-3 kinase/akt signaling”, The Journal of Neuroscience, Vol. 22 No. 22, pp. 9742-53.
57. Monte, A.A., Bronstein, A.C., Dahze, J.C., Heard, K.J., Hoppe, J.A., Hoyte, C.O., Iwanicki, J.L. and Lavonas, E.J. (2014), “Supplementary appendix to – an outbreak of exposure to a novel synthetic cannabinoid”, New England Journal of Medicine, Vol. 370 No. 4, pp. 389-90, available at: www.nejm.org/doi/suppl/10.1056/NEJMc1313655/suppl_file/nejmc1313655_appendix.pdf/ (accessed 20 May 2014)
58. Morgan, C.J.A., Das, R.K., Joye, A., Curran, V. and Kamboj, S.K. (2013a), “Cannabidiol reduces cigarette consumption in tobacco smokers: preliminary findings”, Addictive Behaviours, Vol. 38 No. 9, pp. 2433-6.
59. Morgan, D., Kondabolu, K., Kuipers, A., Sakhuja, R., Robertson, K.L. and Rowland, N.E. (2013b), “Molecular and behavioral pharmacology of two novel orally-active 5HT2 modulators: potential utility as antipsychotic medications”, Neuropharmacology, Vol. 72, pp. 274-81.
60. Murray, R. (2013), “Cannabis, ‘Skunk’ and ‘Spice’: implications for mental health?”, Oral Presentation held at the Second International Conference on Novel Psychoactive Substances, 12-13 September, Swansea
61. Nacca, N., Vatti, D., Sullivan, R., Sud, P., Su, M. and Marraffa, J. (2013), “The synthetic cannabinoid withdrawal syndrome”, Journal of Addiction Medicine, Vol. 7 No. 4, pp. 296-8.
62. Ogata, J., Uchiyama, N., Kikura-Hanajiri, R. and Goda, Y. (2013), “DNA sequence analyses of blended herbal products including synthetic cannabinoids as designer drugs”, Forensic Science International, Vol. 227 Nos 1/3, pp. 33-41.
63. Papanti, D., Schifano, F., Botteon, G., Bertossi, F., Mannix, J., Vidoni, D., Impagnatiello, M., Pascolo-Fabrici, E. and Bonavigo, T. (2013), “Spiceophrenia: a systematic overview of ‘Spice’-related psychopathological issues and a case report”, Human Psychopharmacology: Clinical and Experimental, Vol. 28 No. 4, pp. 379-89.
64. Park, Y., Lee, C., Lee, H., Pyo, J., Jo, J., Lee, J., Choi, H., Kim, S., Hong, R.S., Park, Y., Hwang, B.Y., Choe, S. and Jung, J.H. (2013), “Identification of a new synthetic cannabinoid in a herbal mixture:1-butyl-3- (2-ethoxybenzoyl)indole”, Forensic Toxicology, Vol. 31 No. 2, pp. 187-96.
65. Patton, A.L., Chimalakonda, K.C., Cindy, L., Moran, C.L., McCain, K.R., Radominska-Pandya, A., James, L.P., Kokes, C. and Moran, J.H. (2013), “K2 Toxicity: fatal case of psychiatric complications following AM2201 exposure”, Journal of Forensic Sciences, Vol. 58 No. 6, pp. 1676-80.
66. Peglow, S., Buchner, J. and Briscoe, G. (2012), “Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient”, American Journal on Addiction, Vol. 21 No. 3, pp. 287-8.
67. Pertwee, R.G. (1999), “Pharmacology of cannabinoid receptor ligands”, Current Medicinal Chemistry, Vol. 6 No. 8, pp. 635-64.
68. Pertwee, R.G. (2004), “The pharmacology and therapeutic potential of cannabidiol”, in Di Marzo, V. (Ed.), Cannabinoids, Kluwer Academic/Plenum Publishers, New York, NY, pp. 32-83.
69. Pertwee, R.G. (2008), “The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin”, British Journal of Pharmacology, Vol. 153 No. 2, pp. 199-215.
70. Presley, B.C., Jansen-Varnum, S.A. and Logan, B.K. (2013), “Analysis of synthetic cannabinoids in botanical material: a review of analytical methods and findings”, Forensic Sciences Review, Vol. 25 No. 27, pp. 27-46.
71. Psychonaut Web Mapping Research Group (2010), Psychonaut Web Mapping Project: Final Report, Institute of Psychiatry, King’s College, London
72. Rominger, A., Cumming, P., Xiong, G., Koller, G., Förster, S., Zwergal, A., Karamatskos, E., Bartenstein, P., La Fougère, C. and Pogarell, O. (2013), “Effects of acute detoxification of the herbal blend ‘Spice Gold’ on dopamine D2/3 receptor availability: a [18F]fallypride PET study”, European Neuropsychopharmacology, Vol. 23 No. 11, pp. 1606-10.
73. Rosenbaum, C.D., Scalzo, A.J., Long, C., Weber, J., Jenkins, A., Lopez, G. and Ragone, S. (2011), “K2 & Spice abusers: a case series of clinical and laboratory findings”, paper presented at the North American Congress of Clinical Toxicology (NACCT), 21-26 September, Washington, DC
74. Rubino, T., Zamberletti, E. and Parolaro, D. (2012), “Adolescent exposure to cannabis as a risk factor for psychiatric disorders”, Journal of Psychopharmacology, Vol. 26 No. 1, pp. 177-88.
75. Russo, E.B. (2011), “Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects”, The British Journal of Pharmacology, Vol. 163, pp. 1344-64.
76. Saito, T., Namera, A., Miura, N., Ohta, S., Shota Miyazaki, S., Osawa, M. and Inokuchi, S. (2013), “A fatal case of MAM-2201 poisoning”, Forensic Toxicology, Vol. 31 No. 2, pp. 333-7.
77. Savasman, C.M., Peterson, D.C., Pietak, B.R., Dudley, M.H., Clinton Frazee, C. III and Garg, U. (2014), “Two fatalities due to the use of synthetic cannabinoids alone”, Proceedings of the 66th Annual Scientific Meeting of the American Academy of Forensic Sciences, Seattle, WA, Publication Printers Inc., Denver, CO, 17-22 February 2014, p. 316.
78. Schaefer, N., Peters, B., Bregel, D., Kneisel, S., Auwärter, V., Schmidt, P.H. and Ewald, A.H. (2013), “A fatal case involving several synthetic cannabinoids”, Toxichem Krimtech, Vol. 80, Special Issue, pp. 248-51.
79. Schifano, F. (2013), “‘Bubble troubles’: clinical and pharmacological issues”, Oral Presentation held at the Second International Conference on Novel Psychoactive Substances, 12-13 September, Swansea
80. Schifano, F., Corazza, O., Davey, Z., Deluca, P., Di Furia, L., Farrè, M., Flesland, L., Mannonen, M., Pagani, S., Peltoniemi, T., Pezzolesi, C., Scherbaum, N., Siemann, H., Skutle, A., Torrens, M. and van der Kreeft, P. (2009), “Psychoactive drug or mystical incense? Overview of the online available information on Spice products”, International Journal of Culture and Mental Health, Vol. 2 No. 2, pp. 137-44.
81. Schubart, C., Sommer, I., van Gastel, W., Goetgebuer, R., Kahn, R. and Boks, P.M. (2011), “Cannabis with high cannabidiol content is associated with fewer psychotic experiences”, Schizophrenia Research, Vol. 130 Nos 1-3, pp. 216-21.
82. Seely, K.A., Lapoint, J., Moran, J.H. and Fattore, L. (2012), “Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids”, Progress in Neuro-Psychopharmacology & Biological Psychiatry, Vol. 39 No. 2, pp. 234-43.
83. Seeman, P. (2002), “Atypical antipsychotics: mechanism of action”, Canadian Journal of Psychiatry, Vol. 47 No. 1, pp. 27-38.
84. Shanks, K.G., Dahn, T. and Terrell, A.R. (2012), “Detection of JWH-018 and JWH-073 by UPLC–MS-MS in postmortem whole blood casework”, Journal of Analytical Toxicology, Vol. 36 No. 3, pp. 145-52.
85. Shroomery (2010), “Is spice a hallucinogen?”, available at: www.shroomery.org/forums/showflat.php/Number/13458849/fpart/all/filter/i/vc/1/ (accessed 5 February 2014)
86. Simonato, P., Corazza, O., Santonastaso, P., Corkery, J., Deluca, P., Davey, Z., Blaszko, U. and Schifano, F. (2013), “Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey”, Human Psychopharmacology: Clinical and Experimental, Vol. 28 No. 4, pp. 324-31.
87. Singhal, A.B., Caviness, V.S., Begleiter, A.F., Mark, E.J., Rordorf, G. and Koroshetz, W.J. (2002), “Cerebral vasoconstriction and stroke after use of serotonergic drugs”, Neurology, Vol. 58 No. 1, pp. 130-3.
88. Spaderna, M., Addy, P.H. and D’Souza, D.C. (2013), “Spicing things up: synthetic cannabinoids”, Psychopharmacology, Vol. 228 No. 4, pp. 525-40.
89. Stella, N. (2010), “Cannabinoid and cannabinoid-like receptors in microglia, astrocytes and astrocytomas”, Glia, Vol. 58 No. 9, pp. 1017-30.
90. Steup, C. (2008), “Untersuchung des handelsproduktes ‘Spice’ (Investigation of the commercial product ‘Spice’)”, available at: http://usualredant.de/downloads/analyse-thc-pharm-spice-jwh-018.pdf (accessed 13 February 2014)
91. Substance Abuse and Mental Health Services Administration (2012), The DAWN Report: Drug-Related Emergency Department Visits Involving Synthetic Cannabinoids, SAMHSA
92. Rockville, MD, available at: www.samhsa.gov/data/2k12/DAWN105/SR105-synthetic-marijuana.pdf/ (accessed 15 April 2014)
93. Sumnall, H.R., Evans-Brown, M. and McVeigh, J. (2011), “Social, policy, and public health perspectives on new psychoactive substances”, Drug Testing and Analysis, Vol. 3 Nos 7-8, pp. 515-23.
94. Sundram, S. (2006), “Cannabis and neurodevelopment: implications for psychiatric disorders”, Human Psychopharmacology: Clinical and Experimental, Vol. 21 No. 4, pp. 245-54.
95. Szabo, B., Siemes, S. and Wallmichrath, I. (2002), “Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids”, European Journal of Neuroscience, Vol. 15 No. 12, pp. 2057-61.
96. Thomas, A., Baillie, G.L., Phillips, A.M., Razdan, R.K., Ross, R.A. and Pertwee, R.G. (2007), “Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro”, British Journal of Pharmacology, Vol. 150 No. 5, pp. 613-23.
97. Thornton, S.L., Lo, J., Clark, R.F., Wu, A.H. and Gerona, R.R. (2012), “Simultaneous detection of multiple designer drugs in serum, urine, and CSF in a patient with prolonged psychosis”, Journal of Clinical Toxicology, Vol. 50 No. 10, pp. 1165-8.
98. Uchiyama, N., Kawamura, M., Kikura-Hanajiri, R. and Goda, Y. (2013a), “URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products”, Forensic Science International, Vol. 227 Nos 1/3, pp. 21-32.
99. Uchiyama, N., Matsuda, S., Kawamura, M., Kikura-Hanajiri, R. and Goda, Y. (2013b), “Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative a-PVT and an opioid receptor agonist AH-7921 identified in illegal products”, Forensic Toxicology, Vol. 31 No. 2, pp. 223-40.
100. Uchiyama, N., Shimokawa, Y., Matsuda, S., Kawamura, M., Kikura-Hanajiri, R. and Goda, Y. (2014), “Two new synthetic cannabinoids, AM-2201 benzimidazole analog (FUBIMINA) and (4-methylpiperazin-1-yl) (1-pentyl-1H-indol-3-yl)methanone (MEPIRAPIM), and three phenethylamine derivatives, 25H-NBOMe 3,4,5-trimethoxybenzyl analog, 25B-NBOMe, and 2C-N-NBOMe, identified in illegal products”, Forensic Toxicology, Vol. 32 No. 1, pp. 105-15.
101. Van der Veer, N. and Friday, J. (2011), “Persistent psychosis following the use of Spice”, Schizophrenia Research, Vol. 130 Nos 1/3, pp. 285-6.
102. Vandrey, R., Dunn, K.E., Fry, J.A. and Girling, E.R. (2012), “A survey study to characterize use of Spice products (synthetic cannabinoids)”, Drug and Alcohol Dependence, Vol. 120 Nos 1-3, pp. 238-41.
103. Van Os, J., Bak, M., Hanssen, M., Bijl, R.V., deGraaf, R. and Verdoux, H. (2002), “Cannabis use and psychosis: a longitudinal population-based study”, American Journal of Epidemiology, Vol. 156 No. 4, pp. 319-27.
104. Walker, D., Neighbors, C., Walton, T., Pierce, A., Mbilinyi, L., Kaysen, D. and Roffman, R. (2014), “Spicing up the military: use and effects of synthetic cannabis in substance abusing army personnel”, Addictive Behaviours, Vol. 39 No. 7, pp. 1139-44.
105. Wells, D.L. and Ott, C.A. (2011), “The new marijuana”, Annals of Pharmacotherapy, Vol. 45 No. 3, pp. 414-7.
106. Wikstrom, M., Thelander, G., Dahlgren, M. and Kronstrand, R. (2013), “An accidental fatal intoxication with methoxetamine”, Journal of Analytical Toxicology, Vol. 37 No. 1, pp. 43-6.
107. Wiley, J.L., Marusich, J.A. and Huffman, J.W. (2014), “Moving around the molecule: relationship between chemical structure and in vivo activity of synthetic cannabinoids”, Life Sciences, Vol. 97 No. 1, pp. 55-63.
108. Winstock, A.R. and Barratt, M.J. (2013a), “Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample”, Drug and Alcohol Dependence, Vol. 1 Nos 131(1-2), pp. 106-11.
109. Winstock, A.R. and Barratt, M.J. (2013b), “The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products”, Human Psychopharmacology: Clinical and Experimental, Vol. 28 No. 4, pp. 390-3.
110. Wood, D.M. and Dargan, P.I. (2012), “Understanding how data triangulation identifies acute toxicity of novel psychoactive drugs”, Journal of Medical Toxicology, Vol. 8 No. 3, pp. 300-3.
111. Yip, L. and Dart, C.R. (2014), “Is there something more about synthetic cannabinoids?”, Forensic Toxicology. Zimmermann, U.S
112. Winkelmann, P.R., Pilhatsch, M., Nees, J.A., Spanagel, R. and Schulz, K. (2009), “Withdrawal phenomena and dependence syndrome after the consumption of ‘spice gold’”, Deutsches A¨ rzteblatt International, Vol. 106 No. 27, pp. 464-7.
113. Zuardi, A.W., Crippa, J.A., Hallak, J.E., Moreira, F.A. and Guimar~aes, F.S. (2006), “Cannabidiol, a cannabis sativa constituent, as an antipsychotic drug”, Brazilian Journal of Medical and Biological Research, Vol. 39 No. 4, pp. 421-9.
114. Pertwee, R.G. (2005), “Pharmacological actions of cannabinoids”, Handbook of Experimental Pharmacology, Vol. 168, pp. 1-51